BioNTech SE American Depositary Receipt
0
0
0%

Financials

Income statement

Fiscal date 2024 2023 2022 2021
Total reported revenue 2.8B 3.8B 17.3B 19.0B
Cost of revenue 541.3M 599.8M 3.0B 2.9B
Gross profit 2.2B 3.2B 14.3B 16.1B
Operating expense
Research & development 2.3B 1.8B 1.5B 949.2M
Selling general and admin 599M 557.7M 541.2M 327.2M
Other operating expenses -47.7M -25.8M -66.4M -138.3M
Operating income -595.7M 904.2M 12.3B 14.9B
Non operating interest income
Income 437.6M 357.6M 48.5M 1.5M
Expense 12.6M 16.2M 5.4M
Other income expense -69.4M -67.8M 620.7M 145.1M
Pretax income -677.7M 1.2B 13.0B 15.0B
Tax provision -12.4M 255.8M 3.5B 4.8B
Net income -665.3M 930.3M 9.4B 10.3B
Basic EPS -2.8 3.9 38.8 42.2
Diluted EPS -2.8 3.8 37.8 39.6
Basic average shares 240.2M 240.6M 243.3M 244M
Diluted average shares 240.2M 240.6M 243.3M 244M
EBITDA -297.7M 1.2B 11.8B 14.9B
Net income from continuing op. -677.7M 1.2B 13.0B 15.0B
Minority interests 0
Preferred stock dividends
Access the full /income_statement historical dataset via the API — starting from the Pro plan.
Main market

Exchange is currently active.
Closing in 6 minutes

17:28
00:00
08:55
17:35
23:59

Trading Hours (Monday - Friday):

Pre-market
08:00 - 08:55
Main market
08:55 - 17:35
Post-market
17:35 - 17:50
All times are displayed in the Europe/Vienna timezone (CET, UTC+01:00).